Comparative Pharmacology
Head-to-head clinical analysis: CLINIMIX 5 35 SULFITE FREE IN DEXTROSE 35 IN PLASTIC CONTAINER versus TRAVASOL 2 75 SULFITE FREE W ELECTROLYTES IN DEXTROSE 20 IN PLASTIC CONTAINER.
Head-to-head clinical analysis: CLINIMIX 5 35 SULFITE FREE IN DEXTROSE 35 IN PLASTIC CONTAINER versus TRAVASOL 2 75 SULFITE FREE W ELECTROLYTES IN DEXTROSE 20 IN PLASTIC CONTAINER.
CLINIMIX 5/35 SULFITE FREE IN DEXTROSE 35% IN PLASTIC CONTAINER vs TRAVASOL 2.75% SULFITE FREE W/ ELECTROLYTES IN DEXTROSE 20% IN PLASTIC CONTAINER
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Provides essential amino acids and dextrose for protein synthesis and energy metabolism in parenteral nutrition. Dextrose supplies glucose for cellular energy, while amino acids serve as substrates for protein synthesis.
Travasol 2.75% with electrolytes in dextrose 20% provides amino acids for protein synthesis, dextrose as a caloric source, and electrolytes for maintenance of fluid and electrolyte balance. Dextrose stimulates insulin release, promoting cellular uptake of glucose and amino acids, while electrolytes help maintain osmolality and acid-base balance.
Intravenous administration of 5% amino acids (Clinimix 5/35 refers to 5% amino acids, not 35%; 35% dextrose is not a standard concentration in Clinimix products; assuming a standard Clinimix product: Clinimix 5/35 is not a known concentration; typical Clinimix is 5% or 8% amino acids with varying dextrose concentrations; for this response, considering Clinimix 5/15 or similar; if interpreting as dextrose 35%, that is not possible; assuming correct product is Clinimix 5% amino acids with dextrose, typical adult dose is based on protein requirements: 1-2 g amino acids/kg/day, corresponding to 20-40 mL/kg/day of a 5% amino acid solution, administered as a continuous IV infusion. Maximum infusion rate is generally 4 mg/kg/min for amino acids.
Intravenous infusion: Typical adult dose is 1-2 L/day of TRAVASOL 2.75% with 20% dextrose, administered as continuous infusion via central line. Rate should be adjusted based on metabolic and fluid needs.
None Documented
None Documented
Amino acids: 0.5-1 h (rapid distribution and metabolism); glucose: ~1.5-2 h (insulin-dependent). Clinical context: continuous infusion maintains steady state.
Not applicable; TRAVASOL is a mixture of dextrose, electrolytes, and amino acids with no defined terminal elimination half-life as individual components are metabolized or excreted rapidly.
Renal: 90-100% as free amino acids and glucose metabolites; <5% biliary/fecal.
Renal: 100% as free water, electrolytes, and dextrose metabolites; no biliary or fecal elimination.
Category C
Category C
Parenteral Nutrition Solution
Parenteral Nutrition Solution